Treating asthma by preventing and/or accomodating S-nitrosothiol breakdown
AssigneesUniversity of Virginia Patent Foundation, Duke University, The Medical College of Wisconsin Research Foundation, Inc.
InventorsBenjamin Gaston, Jonathan S. Stamler, Owen W. Griffith
Life of this patent
Estimating the term…
Abstract
Asthma is ameliorated, and mild or moderate asthma is prevented from progressing to more severe asthma by administering agents which prevent and/or accommodate for S-nitrosothiol breakdown.
Claims21
A method for treating a patient with asthma to ameliorate symptoms thereof comprising administering to said patient a therapeutically effective amount of an inhibitor of S-nitrosothiol breakdown except for aurothioglucose, gold sodium thiomalate and Auranofin.
A method for treating patients with mild or moderate asthma to inhibit progression to more severe asthma comprising administering to said patient a therapeutically effective amount of an inhibitor of S-nitrosothiol breakdown except for aurothioglucose, gold sodium thiomalate and Auranofin.
A method for treating a patient with asthma to ameliorate symptoms thereof comprising administering to said patient therapeutically effective amounts of NO donor and of an inhibitor of S-nitrosothiol breakdown.
A method for treating a patient with asthma to ameliorate symptoms thereof comprising administering to said patient a therapeutically effective amount of NO donor which is itself an S-nitrosothiol or which generates an S-nitrosothiol in vivo, which is resistant to breakdown by catalysts which cause S-nitrosothiol breakdown, with the proviso that the NO donor is not S-nitroso-N-acetylpenicillamine.
A method for treating patients with mild or moderate asthma to inhibit progression to more severe asthma comprising administering to said patient therapeutically effective amounts of an NO donor and of inhibitor of S-nitrosothiol breakdown.
A method for treating patients with mild or moderate asthma to inhibit progression to more severe asthma comprising administering to said patient a therapeutically effective amount of an NO donor which is itself an S-nitrosothiol or which generates an S-nitrosothiol in vivo, which is resistant to breakdown by catalysts which cause S-nitrosothiol breakdown, with the proviso that the NO donor is not S-nitroso-N-acetylpenicillamine.
Dependencies are inferred from the claim text.